{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"12.2","value":"5"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"15.8","value":"7.5"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"15.8","value":"7.5"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"15.8","value":"7.5"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"15.8","value":"7.5"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"19.2","value":"10"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Death without evidence of disease progression or recurrence. A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, 180 days, and 365 days post-transplant","title":"Transplant-related Mortality","type":"SECONDARY","unitOfMeasure":"percentage of participants"}